

20th International p53 Workshop

Toronto, Canada
April 27 – May 1, 2026



UHN

Princess
Margaret
Cancer Centre



**Sinai
Health**

SickKids®

The 20th edition of this landmark event will bring together leading scientists, clinicians, and industry experts to explore the latest breakthroughs in TP53's role in human biology and genomics, health and disease and particularly, its evolving pivotal role in cancer therapeutics.

Co-organized by three of Canada's top research institutions – University Health Network (UHN), Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, and The Hospital for Sick Children (SickKids) – the workshop continues a long-standing tradition of excellence in p53 research.

SPEAKERS

John Abrams, Dallas, Texas, USA;
Laura Attardi, Stanford, California, USA;
Vinod Balachandran, New York, New York, USA;
Francis Barr, Oxford, England, UK;
Jason Berman, Ottawa, Ontario, Canada;
Shelley Berger, Philadelphia, Pennsylvania, USA;
Sarah Blagden, Oxford, England, UK;
Giovanni Blandino, Rome, Italy;
Jean-Christophe Bourdon, Dundee, Scotland, UK;
Andrei Budanov, Dublin, Ireland;
Kathleen Burns, Boston, Massachusetts, USA;
Tomer Cooks, Be'er Shava, Israel;
Giannino Del Sal, Trieste, Italy;
Matthias Döbelstein, Göttingen, Germany;
Christine Elschen, Philadelphia, Pennsylvania, USA;
Martin Fischer, Magdeburg, Germany;
Judy Garber, Boston, Massachusetts, USA;
Benjamin Greenbaum, New York, New York, USA;
Andrei Gudkov, Buffalo, New York, USA;
Wei Gu, New York, New York, USA;
Ran Kafri, Toronto, Ontario, Canada;
Batsheva Kerem, Jerusalem, Israel;
David Kirsch, Toronto, Ontario, Canada;
Christian Kratz, Hannover, Germany;

Galit Lahav, Cambridge, Massachusetts, USA;
David Lane, Stockholm, Sweden;
Arnold Levine, Princeton, New Jersey, USA;
Bowen Li, Toronto, Ontario, Canada;
Xin Liu, Oxford, England, UK;
Scott Lowe, New York, New York, USA;
Guillermina Lozano, Houston, Texas, USA;
David Malkin, Toronto, Ontario, Canada;
Jim Manfredi, New York, New York, USA;
Kara Maxwell, Philadelphia, Pennsylvania, USA;
Gerry Melino, Rome, Italy;
Emilie Montellier, Grenoble, France;
Maureen Murphy, Philadelphia, Pennsylvania, USA;
Karen Oegema, San Diego, California, USA;
Moshe Oren, Rehovot, Israel;
Carol Prives, New York, New York, USA;
Trevor Pugh, Toronto, Ontario, Canada;
Raul Rabadan, New York, New York, USA;
Kanaga Sabapathy, Singapore, Singapore;
Daniel Schramek, Toronto, Ontario, Canada;
Galina Selivanova, Stockholm, Sweden;
Andreas Strasser, Melbourne, Australia;
Uri Tabori, Toronto, Ontario, Canada;
Fritz Vollrath, Oxford, England, UK;
Klas Wiman, Stockholm, Sweden

TOPICS

- p53 function and the dark genome
- p53 and Cancer evolution
- p53 Partners and Interactors
- p53 Interception and prevention
- Targeting p53 in human disease
- p53, Immunity and Autoimmunity
- p53 Structure & Function
- p53 and MDM2
- p53 in the clinic
- p53 and Cell Cycle disruption

SPONSORS



PMVPharma



HERBERT IRVING
COMPREHENSIVE CANCER CENTER
COLUMBIA | NewYork-Presbyterian



<https://p53.mshri.on.ca/>

INTERNATIONAL SCIENTIFIC ORGANIZING COMMITTEE

Co-chairs: Dr. David Kirsch (Princess Margaret Cancer Care Centre), Dr. David Malkin (SickKids), Dr. Daniel Schramek (Lunenfeld-Tanenbaum RI)

Laura Attardi, Stanford University; Giovanni Blandino, Regina Elena National Cancer Institute; Kathleen H. Burns, Dana-Farber Cancer Institute; Giannino Del Sal, University of Trieste, IFOM and ICGBE; Batsheva Kerem, The Hebrew University; David Lane, Karolinska Institute; Arnold Levine, Institute for Advanced Study; Guillermina Lozano, MD Anderson Cancer Center; Gerry Melino, University of Tor Vergata, Rome; Moshe Oren, Weizmann Institute of Science; Carol Prives, Columbia University